NEW YORK, Dec. 26 - Sequencing the human genome was widely expected to produce a wealth of new drug targets, and the genomics startups that burst onto the scene in recent years have largely delivered. As a result, the research market for genomics companies is vibrant: Worth just $2 billion two years ago, the market is poised to reach $8 billion by 2004, the need for better technology and marketable drugs and diagnostics fueling the growth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.